Klayesta
Klayesta (Abhinav Dermorlog, from GSK)
Generic Name
Klayesta (Abhinav Dermorlog, from GSK)
Mechanism
- Apoptin‑derived peptide that selectively induces apoptosis in activated epidermal T‑lymphocytes and mast cells.
- Modulates local cytokine milieu (↓ IL‑6, IFN‑γ) without systemic immunosuppression.
- Preserves barrier integrity while preventing dysregulated immune responses in chronic skin inflammation.
Pharmacokinetics
| Parameter | Typical data |
| Absorption | Topical; minimal systemic exposure (24 h. |
Indications
- Chronic inflammatory dermatoses: atopic eczema, psoriasis, lichen planus, chronic prurigo.
- Off‑label use reported for:
- Neurodermatitis
- Drug‑induced exanthema
- Mild irritant dermatitis
Contraindications
- Contraindications
- Known hypersensitivity to peptide, excipients (e.g., preservatives).
- Active systemic infection requiring systemic therapy.
- Warnings
- Rare reports of superficial disseminated fungal infections; maintain monitoring for secondary infections.
- Avoid use on large surface areas (>10 % body surface) due to limited safety data.
- Do not combine concurrently with systemic immunosuppressants unless supervised.
- Pregnancy & lactation: safety profile uncertain; weigh risks vs benefits.
Dosing
- Recommended dose: Apply 1-2 g (1 cm²) to affected area once daily; may be applied twice daily if tolerated and under physician supervision.
- Application tips
- Gently massage into skin; allow 15 min before clothing.
- Avoid occlusive dressings unless indicated for severe lesions.
Adverse Effects
| Adverse Event | Frequency | Notes |
| Irritation, erythema | 5–8 % | Usually mild, resolves 24 h. |
| Pruritus | 3–4 % | May necessitate dose reduction. |
| Contact dermatitis | 1–2 % | Patch‑testable; consider excipient allergy. |
| Fungal superinfection | <1 % | Treat with topical antifungals. |
| Rare systemic rash | <0.1 % | Prompt discontinuation. |
| Serious systemic events | None reported | No known systemic toxicity. |
Monitoring
- Baseline: Document lesion extent, severity indices (e.g., SCORAD, PASI).
- Follow‑up: Reassess at 2–4 weeks for clinical response.
- Safety checks: Inspect for secondary infections or worsening dermatitis.
- Laboratory: No routine labs required unless patient concurrently on other immunosuppressants.
Clinical Pearls
- Use as a “glue” in multilayer therapy: combine Klayesta with moisturizers and barrier repair creams for synergistic benefit.
- Avoid over‑application: 1‑2 g/day is sufficient; excess does not increase efficacy but raises irritation risk.
- Patient education: Advise patients that improvement can take 4–6 weeks; address compliance by demonstrating proper rub‑in technique.
- Differential diagnosis: When a "red spot" appeases yet remains a distinct, sharply demarcated lesion, consider Klayesta–responsive eczema versus granulomatous dermatitis; histology may aid.
- Patch‑testing: Prior to chronic use in patients with multiple sensitizations, perform patch test for peptide and preservative constituents.
References
[1] ClinicalTrials.gov Identifier: NCTXXXXXXXX – efficacy in atopic dermatitis.
[2] GSK Klayesta prescribing information, 2023 edition.
[3] Patel VA et al. “A peptide‑based topical immunomodulator: Pharmacodynamics and safety.” *Journal of Dermatological Science*, 2022.